Measurement of serum calcium concentration after administration of gadoversetamide in dogs

Radiology

Volumn 233, Issue 1, 2004, Pages 158-164

  Wible Jr , James H ^a   Hynes, Michael R ^a  

^a Tyco Healthcare   (United States)

Author keywords

Animals; Calcium; Contrast media, effects; Contrast media, experimental studies; Gadolinium; Magnetic resonance (MR), contrast media

Indexed keywords

CALCIUM; DYE; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERIDOL; GADOVERSETAMIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ARTIFACT; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DOG; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; MALE; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ANALYSIS OF VARIANCE; ANIMALS; CALCIUM; CHELATING AGENTS; COLORING AGENTS; CONTRAST MEDIA; DOGS; FEMALE; GADOLINIUM; GADOLINIUM DTPA; HETEROCYCLIC COMPOUNDS; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; ORGANOMETALLIC COMPOUNDS; PHENOLPHTHALEINS; TIME FACTORS;

EID: 4644327828     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2331031689     Document Type: Article

References (14)

1. Desreux JF, Gilsoul D. Chemical synthesis of paramagnetic complexes. In: Thomsen HS, Muller RN, Mattrey RF, eds. Trends in contrast imaging. Berlin, Germany: Springer-Verlag, 1999; 161-169.
2. Grossman RI, Rubin DL, Hunter G, et al. Mangnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (GD-DTPA). Invest Radiol 2000; 35:412-419.
3. Rubin DL, Desser TS, Semelka R, et al. A multicenter, randomized double-blind study to evaluate the safety, tolerability and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial. J Magn Reson Imaging 1999; 9:240-250.
4. Wible JH Jr, Troup CM, Hynes MR, et al. Toxicological assessment of gadoversetamide injection (OptiMARK): a new contrast-enhancement agent for use in magnetic resonance imaging. Invest Radiol 2001; 36:401-412.
5. Brown JJ, Kristy RM, Stevens GR, Pierro JA. The OptiMARK clinical development program: summary of safety data. J Magn Reson Imaging 2002; 15:446-455.
6. Prince MR, Erel HE, Lent RW, et al. Gadodiamide administration causes spurious hypocalcemia. Radiology 2003; 227: 639-646.
7. Normann PT, Frøysa A, Svaland M. Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium. Scand J Clin Lab Invest 1995; 55:421-426.
8. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990; 8:467-481.
9. Periasamy M, White D, deLearie L, et al. The synthesis and screening of nonionic gadolinium (III) DTPA-bisamide complexes as magnetic resonance imaging contrast agents. Invest Radiol 1991; 26(suppl 1): S217-S220.
10. Lin J, Idee JM, Port M, et al. Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. J Pharm Biomed Anal 1999; 21: 931-943.
11. Swan SK, Baker JF, Free R, et al. Pharmacokinetics, safety and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system of liver pathology and varying degrees of renal function. J Magn Reson Imaging 1999; 9:317-321.
12. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991; 26:975-979.
13. Choyke PL, Knopp MV. Pseudohypocalcemia with MR imaging contrast agents: a cautionary tale. Radiology 2003; 227: 627-628.
14. College of American Pathologists. Participant summary: surveys 2003-C-A chemistry. Northfield, III: College of American Pathologists, 2003; 19.